Better Biopharma

Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.

Tyler Menichiello Episode 8

In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions